UK – The fourth edition of Medicxi fund has been announced, with the 2023/2024 edition been facilitated to a tune of US$400 million, and Medicxi IV will continue to support drug hunters with clear product visions to deliver transformative therapies for patients.
Medicxi IV will be supported by the Medicxi Scientific Advisory Board, which benefits from the scientific and commercial expertise of senior executives from Novartis, the Janssen Pharmaceutical Companies of Johnson & Johnson, GlaxoSmithKline and Verily (an Alphabet company).
The new fund will continue to focus on Medicxi’s pioneering ‘asset-centric’ investment model as well as investing in fully integrated private companies with an underlying platform and/or a pipeline of assets that Medicxi believes can deliver licensed pharmaceutical products to satisfy unmet medical needs.
The size of the fund and the speed with which it was closes reflects the continued maturity of the life sciences sector across Europe, with investors now prioritizing their attention and support for emerging biopharma companies and their efforts to translate breakthrough science into pipelines of new drugs.
Previous editions of Medicxi’s investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson), Blincyto (Amgen), Alunbrig (Takeda), Voquezna (Phathom Pharmaceuticals) and obicetripib (New Amsterdam Pharma).
A number of Medicxi assets have been acquired by global pharmaceutical companies, including Villaris Therapeutics (Incyte), MiroBio (Gilead Sciences) and Versanis Bio (Eli Lilly) within the last twelve months.
Medicxi’s longstanding success has been built on its uniquely strong ties to pharmaceutical companies and its extensive team of world class subject matter experts, drug hunters and developers, who act as partners for the innovators in which they are investing.
Francesco De Rubertis, Co-founder and Partner at Medicxi reiterated, “Our mission is to support the innovative genius of entrepreneurs by providing the critical capital, expertise and experience that form the all-important ‘bridge’ to pharma.”
De Rubertis added that the new fund would consolidates Medicxi’s position as a key operating platform for scientific entrepreneurs and drug hunters and is deliberately sized for our investment model.
Nick Williams, Partner at Medicxi, commented that behind every practice-changing medicine lied a product and a vision for how best to match pharmacology to disease.
“We are excited to continue developing the best of these visions into valuable products sought after by leading global pharmaceutical companies,” Williams expressed.
Giovanni Mariggi, partner at Medicxi, added that Medicxi IV, would continue to work with leading scientists and clinicians to create asset-focused companies based on deep domain expertise.
“Together with our extensive network of drug developers, we will accelerate the development of novel therapies for patients,” Mariggi asserted.
The Medicxi IV Fund a industry propellant
Medicxi is an international investment firm was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.
The last edition, Medicxi III fund, and brought the total funds raised by Medicxi in the last three years to over US$1B.
Medicxi III invested across the full healthcare continuum, from discovery to late stage clinical assets, empowering ambitious scientific entrepreneurs and drug hunters.
Medicxi III was one of the largest biotech funds in Europe and consolidates Medicxi’s position as a key operating platform for scientific entrepreneurs and drug hunters
Moreover, by minimizing complex governance structures and processes that can fetter innovation and create headwinds against scientific breakthroughs: virtual companies and stepwise ‘asset-centric’ financing can provide a conducive environment for early-stage innovation
At the early stages, Medicxi helps start companies under its pioneering asset-centric model and support their development from scientific insight to early clinical studies and Proof-of-Concept (PoC).
On the other hand, the late stage activity is focused on supporting companies that have successfully reached clinical PoC and want to continue building value by developing their compounds independently through pivotal studies, regulatory approvals and launch.
Strong impact on unmet medical needs and the healthy financial returns associated with such significant innovation are the common goals we passionately share with the entrepreneurs we back.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
